The initial pilot phase of the European Medicines Agency’s (EMA) expert panel advice program is set to open for applications on 27 February. It will see 10 successful medtech companies receive advice on their clinical development strategies, with the aim of supporting them in generating the evidence required for successful conformity assessments from EU notified bodies.
The pilot was announced earlier this month, during which time it was stipulated that manufacturers of class III (high-risk) and class IIb devices that administer or remove medicinal products from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?